Jul 19 2013
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that the United States Patent and Trademark Office has issued to Idera patent number 8,486,908, providing both composition of matter and method of use protection for IMO-8400. IMO-8400, an antagonist of Toll-like receptors (TLRs) 7, 8, and 9, is Idera's lead candidate in development for the treatment of autoimmune diseases. IMO-8400 is currently being evaluated in a Phase 2 trial in patients with moderate-to-severe plaque psoriasis.
“Based on its ability to inhibit the inflammation pathways linked to TLRs 7, 8, and 9, IMO-8400 provides a novel approach to the treatment of autoimmune and inflammatory diseases as well as other potential indications.”
"IMO-8400 is a first-in-class antagonist, and we are pleased that the US Patent and Trademark Office recognizes the novelty, utility, and applications of this compound," commented Steven Ritter, Ph.D., J.D., Vice President of Intellectual Property and Business Affairs at Idera. "Based on its ability to inhibit the inflammation pathways linked to TLRs 7, 8, and 9, IMO-8400 provides a novel approach to the treatment of autoimmune and inflammatory diseases as well as other potential indications."
Idera's intellectual property portfolio related to TLR antagonists contains eight issued patents and 29 pending patent applications in countries around the world. These patents and patent applications cover compositions of matter and methods of use.
SOURCE Idera Pharmaceuticals, Inc.
Global leaders gather at the NFCR Summit to drive breakthroughs in cancer care